RxDoctor Payments Data

Richard Horak, MD

Internal Medicine · Auburn, ALNPI 1578651287

Payments from drug & device makers

$441in general payments, 2019–2025

Across 24 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$165
  • Novo Nordisk$53
  • Otsuka America Pharmaceutical, Inc.$45
  • Edwards Lifesciences$44
  • Boehringer Ingelheim$32
  • Mylan Specialty L.p.$21
  • plus $82 from 5 others

What the payments were for

  • Food & beverage$441100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$441 in reported general payments places this provider in the 50th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$50,483
Medicare patients
167
Services billed
1,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$71,868
MounjaroTirzepatide52$64,122
EliquisApixaban63$57,266
TrulicityDulaglutide29$49,539
JardianceEmpagliflozin38$35,730
EntrestoSacubitril/Valsartan34$32,245
LinzessLinaclotide11$9,891
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,582
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$5,746
Xigduo XrDapaglifloz Propaned/Metformin11$4,927
Novolog FlexpenInsulin Aspart21$4,378
Levothyroxine Sodium201$2,773
Atorvastatin Calcium293$2,683
Rosuvastatin Calcium127$2,362
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$53$71,86855 claims
PfizerEliquis$18$57,26663 claims
Boehringer IngelheimJardiance$32$35,73038 claims
AbbVieLinzess$165$9,89111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Auburn

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →